ANI Pharmaceuticals ANIP Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's additional paid-in capital?
- ANI Pharmaceuticals (ANIP) reported additional paid-in capital of $608.43M in Q1 2026.
- How has ANI Pharmaceuticals's additional paid-in capital changed year-over-year?
- ANI Pharmaceuticals's additional paid-in capital increased by 14.6% year-over-year, from $531.06M to $608.43M.
- What is the long-term trend for ANI Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's additional paid-in capital has grown at a 22.7% compound annual growth rate (CAGR), from $214.35M to $596.04M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.